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Interferons (IFNs) are mainly produced by 
immune cells responding to pathogens or 
malignancies and can be subdivided into 
two major, functionally distinct classes: 
Type I and Type II IFNs. Type I IFNs 
(i.e., IFNα, IFNβ) signal via the IFNα/β 
receptor, whereas Type II IFN (IFNγ) 
does so via the IFNγ receptor. Both Type I 
and Type II IFN receptors are made up of 
two subunits (i.e., α and β) that—upon 
engagement—allow for the binding of 
Janus kinase family members, hence driv-
ing the activation of signal transducer and 
activator of transcription (STAT) family 
members. The main function of Type I 
IFNs is to inhibit viral replication. These 
cytokines are indeed predominantly 
secreted by plasmacytoid dendritic cells 
in response to viral nucleic acids. In con-
trast, IFNγ—which is mainly produced 
by activated T and natural killer (NK) 
cells—exerts limited antiviral functions 
but primarily operates as an immuno-
modulator and stimulator of monocyte/
macrophage activity.1
The mutual interactions between 
mature immune cells and hematopoietic 
stem (and progenitor) cells have been 
addressed only recently.2 An early report 
by Binder et al. suggested that IFNα/β 
directly induces a state of transient hema-
topoietic aplasia in mice acutely infected 
with the lymphocytic choriomeningitis 
virus.3 Conversely, recent elegant studies 
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have demonstrated that IFNα induces 
the proliferation of murine hematopoi-
etic stem cells (HSCs) in vivo. The injec-
tion of polyinosinic-polycytidylic acid 
(poly-I:C), mimicking double-stranded 
viral RNA and potently inducing IFNα/β 
production, activated quiescent HSCs in 
an IFNα/β receptor-dependent manner. 
Interestingly, the transient activation of 
HSCs by IFNα did not impair their self-
renewal ability, whereas chronic IFNα 
exposure led to HSC exhaustion due to 
extensive proliferation.4 These results were 
confirmed and extended upon the dem-
onstration that interferon regulatory fac-
tor 2, a transcriptional repressor of IFNα 
signaling, preserves the quiescence and 
multilineage reconstitution capacities of 
HSCs.4 Therefore, Type I IFNs are impor-
tant modulators of HSC proliferation 
and differentiation in response to viral 
infection.
The role of IFNγ in the function of 
HSCs is also controversially discussed. 
In several early studies, IFNγ was shown 
to induce the apoptotic demise or dif-
ferentiation of murine HSCs in vivo as 
well as to suppress the growth and col-
ony-forming potential of human CD34+ 
stem/progenitor cells in vitro. Conversely, 
other reports demonstrated that IFNγ 
potentiates the cytokine-dependent 
proliferation of human CD34+ stem/
progenitor cells in vitro. Furthermore, 
IFNγ appears to play a fundamental role 
in the induction of acquired aplasia and 
anemia of chronic disease (reviewed in 
ref. 5). These findings were extended by 
a recent publication showing that IFNγ 
impairs the self-renewal and prolifera-
tive capacities of murine HSCs in vivo.6 
On the other hand, recent studies using 
well-defined mouse models of physiologi-
cal infection have challenged these find-
ings and have shed new light on the role 
of IFNγ during demand-adapted hema-
topoiesis. During a chronic infection 
with Mycobacterium avium, IFNγ directly 
activated quiescent HSCs and induced 
their proliferation. In addition, HSCs 
from IFNγ-deficient mice displayed a 
less exhausted phenotype than HSCs 
from C57BL/6 mice in secondary trans-
plantation experiments, as indicated by 
their improved re-population capacities.7 
Furthermore, in Ehrlichia muris-infected 
mice, IFNγ facilitated infection-induced 
myelopoiesis to ensure host defenses by 
supporting the replenishment of myeloid 
cells. In addition, in a Plasmodium cha-
baudi-based murine model of malaria, 
IFNγ promoted the emergence of a 
myelo-lymphoid progenitor that generated 
myeloid cells to constrain microbe spread 
(reviewed in ref. 8). Altogether, these 
studies indicate that IFNγ is a potent 
regulator of HSC function and that the 
outcome of infection probably depends 
Interferons not only exert a fundamental role during inflammation and immune responses but also modulate the activity 
of hematopoietic stem cells during homeostatic and demand-adapted hematopoiesis. Identical mechanisms regulate 
the homeostasis and proliferation of leukemic stem cells (LsCs). understanding these mechanisms may lead to novel 
therapeutic approaches against leukemia.
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Figure 1. Interferons in the bone marrow during hematopoietic homeostasis, infection and leukemia. During homeostasis, quiescent hematopoietic 
stem cells (hsCs) in the endosteal niche and activated hsCs in the vascular niche provide a reservoir for the life-long production of all types of mature 
blood cells. upon infection, interferons (IFNs) are produced either locally or systemically, leading to the activation and proliferation of hsCs. During 
leukemia, IFNs are produced in the inflammatory environment of the bone marrow and induce the proliferation of LsCs. BMsC, bone marrow stromal 
cell; eC, endothelial cell; GC, granulocyte; hPC, hematopoietic progenitor cell; LPC, leukemia progenitor cell; LsC, leukemia stem cell; Meg, megakaryo-
cyte; M-Φ, monocyte; NK, natural killer cell; OB, osteoblast; OC, osteoclast; pDC, plasmacytoid dendritic cell; PLt, platelet; rBC, red blood cell; t, t cell.
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We have recently demonstrated in a 
murine CML model that LSCs are acti-
vated and proliferate in response to IFNγ. 
Adoptively-transferred CML-specific 
cytotoxic CD8+ T cells (CTLs) produced 
IFNγ in response to restimulation with 
leukemia antigens in vivo, and the level of 
IFNγ produced in this setting depended 
on the antigen load, i.e., the leukemic 
load. Therefore, adoptive immuno-
therapy using leukemia antigen-specific 
CTLs failed to cure advanced leukemia 
but paradoxically increased LSC num-
bers and accelerated the course of CML. 
The proliferation of LSCs was induced 
by CTL-derived IFNγ. Leukemia could 
only be cured by the transfer of CTLs in 
an early stage of disease, when the levels 
of leukemic antigens and—as a conse-
quence—IFNγ were low. In addition, 
the increase in the proliferation of LSCs 
normally induced by adoptive immuno-
therapy was limited when IFNγ-deficient 
CTLs were transferred. Importantly, 
IFNγ stimulated the proliferation and 
on the infectious agent itself as well as on 
the timing and duration of IFNγ stimula-
tion. Of note, the heterogeneous panels of 
markers used in these studies to identify 
HSCs and progenitors impede a direct 
comparison of the results.5
Before the introduction of tyrosine 
kinase inhibitors (TKIs), IFNα was used 
as standard therapy for chronic myeloid 
leukemia (CML). In combination with 
cytoreductive chemotherapy, the admin-
istration of IFNα induced partial or 
complete cytogenetic responses and sig-
nificantly prolonged the survival of CML 
patients.9 Even in the era of TKIs, quies-
cent, therapy-resistant leukemic stem cells 
(LSCs) can persist in the bone marrow of 
CML patients, de facto representing the 
main cause for disease relapse, drug resis-
tance and therapeutic failure. Therefore, 
the activation of LSCs with IFNα, fol-
lowed by the administration of TKIs or 
other chemotherapeutics, may represent a 
promising strategy to treat CML patients 
at risk of relapse.4
the colony-forming potential of primary 
CD34+ stem/progenitor cells isolated 
from newly diagnosed CML patients, 
confirming the clinical importance of our 
findings.10
In summary, both Type I and Type II 
IFNs directly affect HSC and LSC func-
tions (Fig. 1). However, so far little is 
known about the interplay between 
IFNα/β and IFNγ signaling in the regu-
lation of stem cells and the bone marrow 
stem cell niche during hematopoietic 
homeostasis, infection and leukemia. To 
fully understand the implication of these 
cytokines in hematopoiesis, further inves-
tigations will have to elucidate the com-
mon and individual roles of Type I and 
Type II IFNs. This knowledge will allow 
for the development of novel therapeutic 
interventions against disorders of hema-
topoietic homeostasis including leukemia.
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